N/A
N=200
Chronic Obstructive Pulmonary Disease Patient Preferences Survey
Pulmonary Disease, Chronic Obstructive
Bottom Line
View on ClinicalTrials.gov: NCT02970422 ↗Enrolled (actual)
200
Serious AEs
—
Results posted
Dec 2020
Primary outcome: Primary: Number of Participants Who Prioritized Healthcare Topics — 90; 79; 23; 22 participants — p=.91
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Patient Survey (Other)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- McGill University
- Primary completion
- Oct 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Prioritized Healthcare Topics |
90; 79; 23; 22; 21; 24 | .91 |
| PRIMARY Number of Participants Who Prioritized Research Topics |
113; 98; 28; 29; 26; 30 | .73 |
| PRIMARY Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities |
108; 83; 8; 27; 30; 43 | .05 |
| SECONDARY Forced Expiratory Volume in 1-sec (FEV1) |
49.6; 48.5; 79.0; 55.6; 38.5; 25.2 | .00 sig |
| SECONDARY FEV1/FVC |
49.1; 49.0; 60.5; 53.8; 44.1; 38.1 | .000 sig |
| SECONDARY Modified Medical Research Council Questionnaire on Breathlessness |
45; 40; 20; 15; 7; 3 | .00 sig |
| SECONDARY COPD Assessment Test |
24; 22; 10; 5; 6; 3 | .31 |
| SECONDARY Godin Leisure Time Physical Activity Questionnaire |
74.64; 101.86; 100.29; 117.06; 42.78; 40.06 | .04 sig |
| SECONDARY Satisfaction of Life Questionnaire |
18.62; 18.38; 22.51; 20.94; 16.35; 15.1 | .00 sig |
| SECONDARY Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months |
92; 76; 30; 27; 19; 16 | — |
Summary
The purpose of this study is to distribute a questionnaire created for individuals living with chronic obstructive pulmonary disease (COPD) to assess their activities, participation, and healthcare and COPD-related research priorities. The data collected will be compared across diagnosed COPD stages and disease severity to determine the extent to which adults with COPD participate in the listed activities and identify their primary research and healthcare related priorities. The questionnaire was originally developed based on past research then verified by a panel of COPD and participation experts; as well as, individuals living with COPD in the form of focus groups. The questionnaire will now be administered to 200 individuals living COPD (50 in each GOLD stage) at three sites across Montreal where clinical data for each participant will be available. This phase will help establish the reliability of the questionnaire.
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of COPD
- English or French speaking
- Patient at one of the three participating sites with medical chart
Exclusion Criteria
- No diagnosis of COPD by a healthcare professional
- Unable to communicate in English or French
- Unable to provide informed consent
- No medical chart information at one of the three participating sites
Data sourced from ClinicalTrials.gov (NCT02970422). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.